Linkedin
non-clinical-safety-solutions-logo

Safety Pharmacology, ADME & PK/TK Interpretation

Overview

Understanding how a therapeutic agent behaves within the body—and how it influences critical physiological systems—is essential for constructing a defensible, well-integrated nonclinical safety package. Nonclinical Safety Solutions (NCSS) provides expert guidance in safety pharmacology, pharmacokinetics (PK), and ADME (absorption, distribution, metabolism, and excretion) to support rational study design, accurate data interpretation, and strong regulatory alignment.

Drawing on extensive FDA and industry experience, Dr. Thomas D. Steele applies a highly integrated approach to interpreting these disciplines, ensuring that exposure–response relationships, mechanistic data, and safety findings work together to reinforce your overall safety narrative. NCSS helps teams understand species relevance, identify mechanistic explanations for unexpected observations, and articulate scientifically sound justifications for dosing strategies and clinical progression.

Whether supporting IND planning, troubleshooting unexpected results, or evaluating a novel therapeutic modality, NCSS delivers the insight needed to build a cohesive and regulator-ready nonclinical program.

Core Services Included in Safety Pharmacology / ADME / PK Support

Safety Pharmacology Strategy & Interpretation

  • Identification of core and supplemental safety pharmacology study needs
  • Evaluation of cardiovascular, respiratory, and central nervous system (CNS) findings
  • Interpretation of off-target or secondary pharmacology profiles
  • Recommendations for follow-up studies or mechanistic investigations

ADME Evaluation & Interpretation

  • Guidance on absorption, metabolism, metabolite identification, and bioavailability
  • Integration of in vitro and in vivo ADME data to inform toxicology study design
  • Assessment of species differences and their human relevance
  • Support for impurity/metabolite safety evaluations

Pharmacokinetics (PK) Support

  • PK study planning, dose justification, and exposure margin evaluation
  • Interpretation of TK data generated during toxicology studies
  • Modeling of exposure–response relationships for starting-dose and escalation strategies
  • PK considerations for biologics, small molecules, and emerging therapeutic modalities

Regulatory Contextualization

  • Alignment with FDA, EMA, and ICH expectations (S7A, S7B, S3A, M3, and related guidance)
  • Integration of ADME/PK and safety pharmacology data into IND or Warrant of Safety (WoS) justification
  • Preparation of PK/ADME summaries for regulatory submissions

Troubleshooting & Scientific Rationale Development

  • Investigation of unexpected exposure levels or high PK variability
  • Interpretation of disproportionate or unique metabolites
  • Recommendations for supplemental studies to de-risk clinical development

Why This Service Matters

Regulators expect clear, scientifically sound integration of safety pharmacology, ADME, and PK/TK data within the broader nonclinical safety story. Misinterpretation—or insufficient interpretation—of these datasets can create uncertainty around:

  • Starting dose selection
  • Exposure margins
  • Species relevance
  • Interpretation of toxicology findings
  • Overall clinical risk assessment

NCSS helps development teams avoid these pitfalls by ensuring that the science behind exposure, metabolism, and physiological effects is accurately understood and properly contextualized. Dr. Steele’s deep experience across toxicology, FDA review, PK integration, and mechanistic evaluation enables NCSS to connect these disciplines into a cohesive, compelling safety strategy that supports confident regulatory interactions and informed clinical development.

To discuss your program and receive expert PK/ADME/safety pharmacology support, you may request a consultation at any time.

Frequently Asked Questions

1. Why are safety pharmacology studies required before clinical trials?

Safety pharmacology evaluates a drug’s impact on vital physiological systems (cardiovascular, respiratory, CNS) to ensure patient safety and satisfy regulatory expectations prior to human dosing.

2. What is the difference between PK and TK in toxicology studies?

PK characterizes how a drug moves through the body in dedicated studies, while TK refers to exposure data collected during toxicology studies to correlate systemic exposure with observed findings.

3. When is supplemental safety pharmacology needed beyond the core battery?

Additional studies may be required when mechanistic concerns arise, off-target activity is identified, or toxicology findings suggest organ-specific risk.

4. How does ADME data influence toxicology study design?

ADME assists in species selection, dose level decisions, exposure margin evaluation, metabolite coverage, and determining the human relevance of toxicology findings.

5. Why do regulators focus on exposure margins?

Exposure margins indicate whether toxicities occur at exposures relevant to clinical use, informing dose selection and risk management strategies.

6. Can NCSS help interpret unusual PK or TK data?

Yes. NCSS specializes in evaluating atypical exposure profiles, disproportionate metabolites, and species-specific differences to determine their impact on clinical risk and regulatory strategy.

Expertise

Contact Us

To learn how NCSS can support your nonclinical and regulatory strategy, request a consultation